Wintrust Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

Wintrust Investments’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$597K	Buy	1,937 +900	+87%	+$253K	0.53%	38
2024 Q3	$220K	Sell	1,037 -20,333	-95%	-$5.2M	0.16%	120
2024 Q2	$5.99M	Buy	21,370 +2,100	+11%	+$500K	0.49%	37
2024 Q1	$5.15M	Sell	19,270 -1,250	-6%	-$295K	0.45%	45
2023 Q4	$4.75M	Sell	20,520 -5,365	-21%	-$939K	0.46%	40
2023 Q3	$3.78M	Buy	25,885 +17,500	+209%	+$3.29M	0.4%	53
2023 Q2	$1.94M	Buy	8,385 +2,035	+32%	+$551K	0.19%	104
2023 Q1	$1.54M	Buy	6,350 +600	+10%	+$163K	0.2%	100
2022 Q4	$1.67M	Buy	+5,750	New	+$562K	0.22%	92

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wintrust Investments's MDGL Position: Q4 2024 in Review

Wintrust Investments increased its Madrigal Pharmaceuticals (MDGL) stake by 87% in Q4 2024, buying an estimated $253K and bringing the position to 1,937 shares worth $597K. The position accounts for 0.53% of the portfolio, ranked #38.

Wintrust Investments first reported a position in MDGL in Q4 2022 and has held it in 9 quarters since. The position peaked at $5.99M in Q2 2024. 283 funds tracked by Wall St. Rank hold MDGL as of Q4 2024.

Wintrust Investments held 1,937 shares of Madrigal Pharmaceuticals worth $597K as of Q4 2024.
Wintrust Investments bought 900 Madrigal Pharmaceuticals shares in Q4 2024, an estimated $253K.
Madrigal Pharmaceuticals made up 0.53% of Wintrust Investments's portfolio in Q4 2024, its #38 holding.
Wintrust Investments first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
Wintrust Investments's Madrigal Pharmaceuticals position peaked at $5.99M in Q2 2024.
283 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2024.

Based on Wintrust Investments's 13F filing for Q4 2024, filed 10 Feb 2025.